Literature DB >> 31757376

Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.

Jing Luo1, Dejian Gu2, Huasong Lu1, Si Liu1, Jinliang Kong3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31757376     DOI： 10.1016/j.jtho.2019.07.021

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  7 in total

1.  Next Generation Sequencing Reveals a Synchronous Trilateral Lung Adenocarcinoma Case with Distinct Driver Alterations of EGFR 19 Deletion or EGFR 20 Insertion or EZR-ROS1 Fusion.

Authors:  Xuhui Zhang; Jiemei Feng; Xiaoxing Su; Yan Lei; Wendy Wu; Xiangyang Cheng
Journal:  Onco Targets Ther       Date:  2020-12-09       Impact factor: 4.147

2.  Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report.

Authors:  Xuan Wu; Hanqiong Zhou; Zhen He; Zhe Zhang; Wen Feng; Jiuzhou Zhao; Haiyang Chen; Shuai Wang; Wei Wang; Qiming Wang
Journal:  Transl Lung Cancer Res       Date:  2020-12

3.  Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer.

Authors:  Jin Kang; Xu-Chao Zhang; Hua-Jun Chen; Wen-Zhao Zhong; Yang Xu; Jian Su; Qing Zhou; Hai-Yan Tu; Zhen Wang; Chong-Rui Xu; Xue-Ning Yang; Zhi-Hong Chen; Xue Wu; Xian Zhang; Yang Shao; Yi-Long Wu; Jin-Ji Yang
Journal:  Front Oncol       Date:  2020-12-11       Impact factor: 6.244

4.  Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.

Authors:  Hong Tao; Zhe Liu; Jing Mu; Fei Gai; Zhan Huang; Liang Shi
Journal:  Diagn Pathol       Date:  2022-02-10       Impact factor: 2.644

5.  Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib.

Authors:  Long Xu; Xiaoxia Chen; Hong Huo; Yongye Liu; Xiaodan Yang; Dejian Gu; Mingming Yuan; Min Zhang; Rongrong Chen; Jiayin Wang; Zhendong Zheng
Journal:  Front Med (Lausanne)       Date:  2021-09-20

6.  Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.

Authors:  Xueqian Wu; Weiya Wang; Bingwen Zou; Yanying Li; Xiaojuan Yang; Ning Liu; Qizhi Ma; Xiaoxuan Zhang; Yongsheng Wang; Dan Li
Journal:  Thorac Cancer       Date:  2020-03-24       Impact factor: 3.500

7.  Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.

Authors:  Shangkun Ning; Congcong Shi; Huifang Zhang; Jinpeng Li
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.